Microenvironment switches cancer cells to a drug-resistant state
A new study has revealed that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.
Traditionally, epigenetic changes have been thought to arise from internal cellular processes, such as histone methylation or DNA acetylation, or from biochemical signals like growth factors or metabolites within the tumour microenvironment.
A new study led by Miranda Hunter, Memorial Sloan Kettering Cancer Center, and Ludwig Oxford’s Richard White, used a zebrafish model of melanoma to show that when tumour cells are tightly confined by surrounding tissues, they undergo structural and functional changes.
Rather than continuing to divide rapidly, the cells activate a programme of ‘neuronal invasion’, enabling them to migrate and spread into the surrounding tissue.
At the centre of this transformation is HMGB2: a DNA-bending protein. The study demonstrates that HMGB2 responds to the mechanical stress of confinement by binding to chromatin, altering how genetic material is packaged.
This exposes regions of the genome linked to invasiveness. As a result, cells with high levels of HMGB2 become less proliferative but more invasive and resistant to treatment.
Need to prevent the invasive transformation
The team also found that melanoma cells adapt to this external pressure by remodelling their internal skeleton, forming a cage-like structure around the nucleus.
This protective shield involves the LINC complex, a molecular bridge that connects the cell’s skeleton to the nuclear envelope, helping to protect the nucleus from rupture and DNA damage caused by confinement-induced stress.
Richard White, Professor of Genetics and lead author, said: “Cancer cells can rapidly switch between different states, depending on cues within their environment. Our study has shown that this switch can be triggered by mechanical forces within the tumour microenvironment.
“This flexibility poses a major challenge for treatment, as therapies targeting rapidly dividing cells may miss those that have transitioned to an invasive, drug-resistant phenotype. By identifying the factors that are involved in this switch, we hope to able to develop therapies that prevent or even reverse the invasive transformation.”
